LI
INDP icon

Leap Investments’s Indaptus Therapeutics INDP Stock Holding History

Leap Investments’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6
Closed -$60K – 441
2019
Q2 		$60K Buy
+6
New +$75.7K 0.08% 228

Other funds holding INDP

MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Leap Investments's INDP Position: Q3 2019 in Review

Leap Investments sold out of Indaptus Therapeutics (INDP) in Q3 2019, closing a stake of 6 shares — an estimated $60K sold.

Leap Investments first reported a position in INDP in Q2 2019 and held it in 1 quarter. The position peaked at $60K in Q2 2019. 33 funds tracked by Wall St. Rank hold INDP as of Q3 2019.

  • Leap Investments reported no remaining Indaptus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Leap Investments sold 6 Indaptus Therapeutics shares in Q3 2019, an estimated $60K.
  • Leap Investments first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 1 quarter.
  • Leap Investments's Indaptus Therapeutics position peaked at $60K in Q2 2019.
  • 33 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.